Search Results

You searched for : Lynparza

	Lynparza approved in China for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer ... Jun 24
	LYNPARZA (olaparib) Approved in China for the Treatment of Certain Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer Only PARP Inhibitor to Demonstrate Overall Survival Versus New Hormonal Treatments in BRCA1/2-Mutated Advanced Prostate Cancer... Jun 24
	LYNPARZA (olaparib) Receives Three New Approvals in Japan LYNPARZA has been approved in Japan for the treatment of three types of advanced cancer: ovarian, prostate and pancreatic cancer.... Dec 28
	Lynparza approved in the EU as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer Lynparza in combination with bevacizumab demonstrated as a treatment for the treatment of HRD-positive advanced Ovarian Cancer... Nov 05
	LYNPARZA Approved in the EU for Treatment of BRCA1/2-Mutated Metastatic Castration-Resistant Prostate Cancer Only PARP Inhibitor to Demonstrate Overall Survival Versus New Hormonal Agent Treatments in BRCA1/2-Mutated mCRPC... Nov 05
	DCGI approves AstraZeneca Olaparib tablets for ovarian and breast cancer AstraZeneca's patented olaparib for ovary and breast cancer now in India... Aug 20
	Positive About COVID-19 Vaccine, Says UK Pharma Firm AstraZeneca has already reached deals with countries to make more than 2 billion doses of its COVID-19 vaccine with Oxford Univeristy ... Jul 31
	AstraZeneca-Merckâ€™s Lynparza wins EU approval for pancreatic cancer Pancreatic cancer is a rare, life-threatening disease with the lowest survival rate among the most common cancers. ... Jul 08
8 Matching result(s) found!

-Advertisements-

Trending Now
	The Hidden Struggles of Parenthood: Addressing Isolation, Loneliness, and BurnoutApril 25, 2024
	FDA Confirms Bird Flu Virus Remnants in Pasteurized Milk: Safety and Regulatory InsightsApril 24, 2024
	Sarvodaya Hospital Redefines Total Knee Replacement Surgery with Augmented Reality April 23, 2024
	Fateh Education announces partnership to expand educational opportunities for Indian studentsApril 23, 2024
	10 Strategies to counter disinformation for the healthcare digital ecosystemApril 23, 2024
	Is Selling Over-the-Counter (OTC) Drugs in General Stores A Step Towards Affordable Healthcare in IndiaApril 23, 2024
	Student Health Crisis: Food Poisoning Incident Strikes Pune Coaching CentreApril 23, 2024
	The Impact of Diabetes on Kidney Health: Diabetic Nephropathy ExplainedApril 23, 2024
	Toddler Hospitalized After Consuming Expired Chocolates: Health Concerns RaisedApril 23, 2024
	After months of diagnostic delay, a migrant worker could access TB services only when a community health worker met himApril 22, 2024
	Indian Spices Contaminated with Cancer-Causing Chemical: Hong Kong Food Regulators Issue WarningApril 22, 2024
	FTCCI organised a Workshop on Rooftop Kitchen GardeningApril 20, 2024
	Children in Cities Exposed to Elevated Lead Levels: Study Reveals Urgent Health ConcernApril 20, 2024
	Biocon Ventures into Weight-Loss Drug Market with Semaglutide DevelopmentApril 20, 2024
	Innovative AI Assistance Empowers Moscow Doctors to Detect Cervical Spine Issues through MRI ScansApril 20, 2024
	Air India Express ties up with AISATS for AeroWash Automated Aircraft Exterior Cleanings April 19, 2024
	IndoSup raises strategic funding led by CCI group promoters Naresh Sharma and Satish Sharma; investors include Yatra.com’s Rohan Mittal April 19, 2024
	10 compelling reasons why choosing right media platform Is important in healthcareApril 19, 2024
	Protecting Public Health: Proposed Guidelines for Pharmaceutical Product DistributionApril 19, 2024
	What is Haemophilia: A Genetic Bleeding Disorder that has Affected 1,36,000 IndiansApril 19, 2024

Search Results

Lynparza approved in China for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer

LYNPARZA (olaparib) Approved in China for the Treatment of Certain Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

LYNPARZA (olaparib) Receives Three New Approvals in Japan

Lynparza approved in the EU as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer

LYNPARZA Approved in the EU for Treatment of BRCA1/2-Mutated Metastatic Castration-Resistant Prostate Cancer

DCGI approves AstraZeneca Olaparib tablets for ovarian and breast cancer

Positive About COVID-19 Vaccine, Says UK Pharma Firm

AstraZeneca-Merckâ€™s Lynparza wins EU approval for pancreatic cancer

Trending Now